Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes
Arthritis Care & Research · 14.10.2026
DOI: 10.1002/acr.80190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 14.10.2026. Verfasst von George J Greene und 5 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract (Originalsprache)
Objective
Existing patient‐reported outcome (PRO) measures for systemic sclerosis (SSc) have important limitations, including inadequate coverage of early disease and limited inclusion of diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subtypes. This paper reports on the development of two PRO measures for early SSc in the Clinical Outcome Assessments for Systemic Sclerosis Clinical Trials (COAST) study, following regulatory guidance for clinical outcome assessments.
Methods
Concept elicitation interviews were conducted with 42 individuals with dcSSc or lcSSc within 7 years of disease onset. Data were analyzed using a constant comparative approach. The concept prioritization scheme integrated symptom frequency, bother and health‐related quality of life ratings, subgroup analyses, and clinical expert input. Priority concepts were mapped to items from item libraries (PROMIS®, FACIT) and SSc‐specific measures, with new items developed during measure refinement. The item pool was reduced through expert consensus.
Results
Across SSc subtypes, participants reported 52 symptoms and treatment side effects, spanning 16 domains. Raynaud's phenomenon was the most frequently reported symptom (81.0%), followed by swelling and pain (66.7% each); among the five most frequently reported symptoms, fatigue was rated most bothersome (mean=7.20, 0‐10 scale). Participants also reported 57 physical function impacts across 8 domains, and 16 socioemotional concerns across 4 domains. Two candidate measures were constructed: COAST Scleroderma Symptom Questionnaire (33 items) and COAST Scleroderma Function and Mood Questionnaire (20 items).
Conclusions
The COAST measures address important gaps in SSc measurement, with content validity established through systematic patient input. The measures were designed for use in clinical trials to assess treatment benefit in early SSc.
Autor:innen und Institutionen
- Northwestern University Feinberg School of Medicine, Chicago, IL.
- University of Michigan Scleroderma Program, Ann Arbor, MI.
- University of Michigan, Ann Arbor, MI.
ORCID-Profile: George J Greene, Dinesh Khanna
Zitieren
APA
Greene, G. J., Perschon, C. R., Jaeger, E., Lescoat, A., Cella, D., & Khanna, D. (2026). Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes. Arthritis Care & Research. https://doi.org/10.1002/acr.80190
Vancouver
Greene GJ, Perschon CR, Jaeger E, Lescoat A, Cella D, Khanna D. Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes. Arthritis Care & Research. 2026. doi:10.1002/acr.80190
BibTeX
@article{Greene2026,
author = {Greene, George J and Perschon, Chelsea Rose and Jaeger, Emilie and Lescoat, Alain and Cella, David and Khanna, Dinesh},
title = {Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.80190}
}
EUVIMED